Terns Pharmaceuticals, Inc. · NASDAQ:TERN
Soleus Capital Master Fund, L.P. reported a 9.60% stake in Terns Pharmaceuticals, Inc. (Schedule 13G/A)
Event Dec 31, 2024 · Filed Feb 11, 2025
Soleus Capital Master Fund, L.P. reported a 9.60% stake in Terns Pharmaceuticals, Inc., 8,142,500 shares, as a passive investor on Dec 31, 2024. Filed Feb 11, 2025 (Schedule 13G/A).
- Stake
- 9.60%
- Shares
- 8,142,500
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 6 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Soleus Capital Master Fund, L.P. | 9.60% | 8,142,500 |
| Soleus Capital, LLC | 9.60% | 8,142,500 |
| Soleus Capital Group, LLC | 9.60% | 8,142,500 |
| Soleus Capital Management, L.P. | 9.60% | 8,142,500 |
| Soleus GP LLC | 9.60% | 8,142,500 |
| Guy Levy | 9.60% | 8,142,500 |
Source
Related
- Terns Pharmaceuticals, Inc.
- Soleus Capital Master Fund, L.P.
- Terns Pharmaceuticals, Inc. shareholders
- Schedule 13G/A · Soleus Capital Master Fund, L.P. · Feb 12, 2026
- Schedule 13G/A · Morgan Stanley · Jun 5, 2026
- Schedule 13G/A · Adage Capital Management, L.P. · May 13, 2026
- Schedule 13G/A · Morgan Stanley · May 12, 2026
- Form 4 · Kuriakose Emil · May 5, 2026
- Form 4 · Gengos Andrew · May 5, 2026